- Home
- MAX vs PLRX Comparison
MAX vs PLRX Comparison
Compare MAX & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAX | PLRX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.8M | 93.3M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MAX | PLRX |
|---|---|---|
| Price | $11.39 | $1.29 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 11 |
| Target Price | ★ $17.00 | $3.79 |
| AVG Volume (30 Days) | 394.2K | ★ 915.7K |
| Earning Date | 02-23-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,123,093,000.00 | N/A |
| Revenue This Year | $30.80 | N/A |
| Revenue Next Year | $8.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 64.86 | N/A |
| 52 Week Low | $7.33 | $1.10 |
| 52 Week High | $13.92 | $12.88 |
Technical Indicators
Market Signals| Indicator | MAX | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.86 | 46.70 |
| Support Level | $11.18 | $1.26 |
| Resistance Level | $11.80 | $1.38 |
| Average True Range (ATR) | 0.48 | 0.06 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 10.99 | 46.83 |
Price Performance
Historical ComparisonAbout MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.